ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,218Medicare Part D Prescriptions Filled, Including Refills

Rank: 4 out of 181

$1.68M Total Retail Price of All Prescriptions

Rank: 1 out of 181

680 Patients Receiving at Least One Drug in Part D
66%Patients 65 Years and Older
61% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 680 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

1% of this provider’s 9,548 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

37% of this provider’s prescriptions were for brand-name drugs, compared to an average of 43%.

Prescription Price

$118 was the average price of a prescription from this provider, compared to $106 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
LISINOPRIL 871 546 1 5
SIMVASTATIN 752 458 2 3
METFORMIN HCL 633 363 3 2
CARVEDILOL 624 494 4 44
LEVOTHYROXINE SODIUM 617 307 5 1
INSULIN SYRINGE 572 331 6 4
METFORMIN HCL ER 510 336 7 13
ATORVASTATIN CALCIUM 508 369 8 19
PEN NEEDLE 377 253 9 7
ZETIA 375 272 10 56
GLIMEPIRIDE 341 227 11 21
AMLODIPINE BESYLATE 308 265 12 11
LEVOXYL 307 216 13 8
FENOFIBRATE 269 179 14 50
PRAVASTATIN SODIUM 264 138 15 26
CRESTOR 256 181 16 35
NIASPAN 255 137 17 88
HYDROCHLOROTHIAZIDE 254 188 18 16
NOVOLOG 242 139 19 24
LEVEMIR 237 180 20 58
ALENDRONATE SODIUM 229 192 21 20
HUMALOG 225 144 22 9
LEVEMIR FLEXPEN 224 144 23 37
SYNTHROID 220 167 24 12
BYETTA 214 132 10 25 49
NOVOLOG FLEXPEN 194 134 26 25
ACTOS 182 113 27 40
JANUVIA 181 113 28 15
PRANDIN 177 140 29 78
METHIMAZOLE 163 117 30 27
HUMULIN R 161 45 31 61
LANTUS 153 76 32 6
NOVOFINE 32 146 103 10 33 98
LOSARTAN POTASSIUM 135 115 34 30
RAMIPRIL 116 76 35 110
LIPITOR 111 87 36 92
NATEGLINIDE 110 78 37 130
PIOGLITAZONE HCL 100 60 R 38 63
DIOVAN 98 92 39 41
NIFEDIAC CC 96 69 40 136
QUINAPRIL HCL 95 85 41 84
NIFEDIPINE ER 92 69 42 85
FUROSEMIDE 91 55 43 18
TORSEMIDE 84 62 44 140
HUMALOG MIX 75-25 80 39 45 39
NOVOLOG MIX 70-30 78 61 46 73
GLIPIZIDE ER 70 54 47 33
LANTUS SOLOSTAR 68 27 48 10
SPIRONOLACTONE 65 41 49 68
DILTIAZEM 24HR ER 62 49 50 90
SYMLINPEN 120 59 44 51 163
LOVAZA 53 18 52 173
ONGLYZA 53 53 52 173
HUMALOG MIX 50-50 53 42 52 131
LOVASTATIN 50 37 55 46
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 2, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.